Dendritic cells (DCs), the most potent antigen-presenting cells in vivo, are capable of inducing immune responses and maintain immunological memory. Antigen presenting in association with DCs induce antigen-specific immune responses   in vivo when these can not be achieved by administration of only antigens or vaccines. Due to these unique properties, DCs are now loaded with tumor antigen (tumor antigen-pulsed DCs) and administered to patients with cancers. Some investigators have shown that tumor antigen-pulsed DCs induce antigen-specific immune responses in cancer patients. However, the overall therapeutic efficacy of tumor antigen-pulsed DCs are not satisfactory. Moreover, the real therapeutic potential of tumor antigen-pulsed DCs are confusing. Here, we will first describe about the concept of treatment of cancer by tumor antigen-pulsed DCs. Next, we will discuss about the limitations of the present regimens of DC-based therapy against cancers. These will provide insights to develop more potent regimens of DC-based therapy against cancer.